Phenotype plasticity as enabler of melanoma progression and therapy resistance

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Clonal evolution in cancer

Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · see citing works

Genomic classification of cutaneous melanoma

Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476 · see citing works

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,198 · see citing works

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works

Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry

Maniotis, A. J., Folberg, R., Hess, A. R., Seftor, E. A., Gardner, L. M. G., Pe’er, J., Trent, J. M., Meltzer, P. S., & Hendrix, M. J. C. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65173-5 · Cited by 2,049 · see citing works

Molecular classification of cutaneous malignant melanoma by gene expression profiling

Bittner, M. L., Meltzer, P. S., Chen, Y., Jiang, Y. Y., Seftor, E. A., Hendrix, M. J. C., Radmacher, M. D., Simon, R., Zohar Yakhini, B., Ben‐Dor, A., et al. (2000) · Nature · doi:10.1038/35020115 · Cited by 1,989 · see citing works

High frequency of BRAF mutations in nevi

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · see citing works

Identification of the tumour transition states occurring during EMT

Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Keymeulen, A. V., Brown, D. V., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,488 · see citing works

Targeting metastasis-initiating cells through the fatty acid receptor CD36

Pascual, G., Avgustinova, A., Mejetta, S., Martı́n, M., Castellanos‐Martín, A., Attolini, C. S., Berenguer, A., Prats, N., Toll, A., Hueto-Madrid, J. A., et al. (2016) · Nature · doi:10.1038/nature20791 · Cited by 1,430 · see citing works

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,261 · see citing works

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,243 · see citing works

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · see citing works

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

Roesch, A., Fukunaga‐Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P. A., VOGT, T. M., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,162 · see citing works

Targeting the cancer epigenome for therapy

Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,132 · see citing works

Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma

Weeraratna, A. T., Jiang, Y., Hostetter, G. H., Rosenblatt, K. P., Duray, P. H., Bittner, M. L., & Trent, J. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00045-4 · Cited by 960 · see citing works

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938 · see citing works

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 904 · see citing works

From melanocytes to melanomas

Shain, A. H., & Bastian, B. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.37 · Cited by 897 · see citing works

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · see citing works

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818 · see citing works

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771 · see citing works

Prospective Identification, Isolation by Flow Cytometry, and In Vivo Self-Renewal of Multipotent Mammalian Neural Crest Stem Cells

Morrison, S. J., White, P. M., Zock, C., & Anderson, D. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80583-8 · Cited by 749 · see citing works

<i>In vivo</i> Switching of Human Melanoma Cells between Proliferative and Invasive States

Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743 · see citing works

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · see citing works

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730 · see citing works

PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress

Vazquez, F., Lim, J.-H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C. B., Granter, S. R., Widlund, H. R., Spiegelman, B. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.020 · Cited by 715 · see citing works

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

Boiko, A. D., Razorenova, O. V., van de Rijn, M., Swetter, S. M., Johnson, D. L., Ly, D. P., Butler, P. D., Yang, G. P., Joshua, B., Kaplan, M. J., et al. (2010) · Nature · doi:10.1038/nature09161 · Cited by 714 · see citing works

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670 · see citing works

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639 · see citing works

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

Landsberg, J., Sirokay, J. D., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 635 · see citing works

Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma

Bald, T., Quast, T., Landsberg, J., Rogava, M., Glodde, N., Lopez-Ramos, D., Kohlmeyer, J., Riesenberg, S., van den Boorn-Konijnenberg, D., Hömig-Hölzel, C., et al. (2014) · Nature · doi:10.1038/nature13111 · Cited by 623 · see citing works

Mitf regulation of Dia1 controls melanoma proliferation and invasiveness

Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes &amp; Development · doi:10.1101/gad.406406 · Cited by 608 · see citing works

Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized

Quintana, E., Shackleton, M. J., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., & Morrison, S. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.012 · Cited by 599 · see citing works

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 596 · see citing works

Tumorigenesis: it takes a village

Tabassum, D. P., & Polyák, K. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3971 · Cited by 558 · see citing works

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature

Hoek, K. S., Schlegel, N. C., Brafford, P. A., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 543 · see citing works

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O. O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 526 · see citing works

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d’Hayer, B., Mohamdi, H., Remenieras, A., et al. (2011) · Nature · doi:10.1038/nature10539 · Cited by 526 · see citing works

A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma

Caramel, J., Papadogeorgakis, E., Hill, L., Browne, G. J., Richard, G., Wierinckx, A., Saldanha, G. S., Osborne, J. E., Hutchinson, P. J., Tse, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.018 · Cited by 516 · see citing works

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489 · see citing works

Therapy-induced tumour secretomes promote resistance and tumour progression

Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M., Wiesner, T., Rosen, N. X., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 485 · see citing works

Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome

Winnepenninckx, V. J. L., Lazar, V., Michiels, S., Dessen, P., Stas, M., Alonso, S. R., Avril, M., Ortiz-Romero, P. L., Robert, T., Bălăcescu, O., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj103 · Cited by 479 · see citing works

The gene expression signatures of melanoma progression

Haqq, C. M., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D. B., Pulliam, B., Federman, S., Miller, J. R., Allen, R. E., Singer, M. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501564102 · Cited by 435 · see citing works

Oxygen availability and metabolic adaptations

Nakazawa, M. S., Keith, B., & Simon, M. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.84 · Cited by 431 · see citing works

Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility

Kaur, A., Ecker, B. L., Douglass, S. M., Kugel, C. H., Webster, M. R., Almeida, F. V., Somasundaram, R., Hayden, J. E., Ban, E., Ahmadzadeh, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0193 · Cited by 421 · see citing works

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma

Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O. V., Zoete, V., et al. (2011) · Nature Genetics · doi:10.1038/ng.1026 · Cited by 410 · see citing works

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

Bogunovic, D., O’Neill, D. W., Belitskaya‐Lévy, I., Vacic, V., Yu, Y.-L., Adams, S., Darvishian, F., Berman, R. S., Shapiro, R. L., Pavlick, A. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905139106 · Cited by 386 · see citing works

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · see citing works

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization

Zhao, F. L., Xiao, C., Evans, K. S., Theivanthiran, T., DeVito, N. C., Holtzhausen, A., Liu, J., Liu, X., Boczkowski, D., Nair, S. K., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.004 · Cited by 286 · see citing works

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

Shain, A. H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, Z., Chung, J., Wang, N. J., Kakavand, H., Mann, G. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3382 · Cited by 284 · see citing works

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

Jönsson, G. B., Busch, C., Knappskog, S., Geisler, J., Miletić, H., Ringnér, M., Lillehaug, J. R., Borg, Å., & Lønning, P. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2509 · Cited by 283 · see citing works

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF

Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T. R., & Marais, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002734 · Cited by 276 · see citing works

Senescent cells develop a parp-1 and nuclear factor-κB-associated secretome (PNAS).

Ohanna, M., Giuliano, S., Bonet, C., Imbert, V., Hofman, V., Zangari, J., Bille, K., Robert, C., Bressac-de Paillerets, B., Hofman, P., et al. (2011) · Genes &amp; Development · doi:10.1101/gad.625811 · Cited by 267 · see citing works

Novel MITF targets identified using a two‐step DNA microarray strategy

Hoek, K. S., Schlegel, N. C., Eichhoff, O. M., Widmer, D. S., Praetorius, C., Einarsson, S. O., Valgeirsdóttir, S., Bergsteinsdóttir, K., Schepsky, A., Dummer, R., et al. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00505.x · Cited by 262 · see citing works

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 239 · see citing works

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanomaPreprint

Falletta, P., Sánchez‐del‐Campo, L., Chauhan, J. S., Effern, M., Kenyon, A., Kershaw, C. J., Siddaway, R., Lisle, R., Freter, R., Daniels, M. J., et al. (2017) · Genes & Development · doi:10.1101/gad.290940.116 · Cited by 239 · see citing works

Key Roles for Transforming Growth Factor β in Melanocyte Stem Cell Maintenance

Nishimura, E. K., Suzuki, M., Igras, V., Du, J., Lonning, S. M., Miyachi, Y., Roes, J., Beermann, F., & Fisher, D. E. (2010) · Cell stem cell · doi:10.1016/j.stem.2009.12.010 · Cited by 235 · see citing works

Skin aging and natural photoprotection

Wulf, H. C., Sandby‐Møller, J., Kobayasi, T., & Gniadecki, R. (2003) · Micron · doi:10.1016/j.micron.2003.11.005 · Cited by 233 · see citing works

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

Zhu, J., de Tenbossche, C. P., Canè, S., Colau, D., van Baren, N., Lurquin, C., Schmitt‐Verhulst, A., Liljeström, P., Uyttenhove, C., & den Eynde, B. J. V. (2017) · Nature Communications · doi:10.1038/s41467-017-00784-1 · Cited by 233 · see citing works

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

Chéli, Y., Guiliano, S., Botton, T., Rocchi, S., Hofman, V., Hofman, P. M., Bahadoran, P., Bertolotto, C., & Ballotti, R. (2011) · Oncogene · doi:10.1038/onc.2010.598 · Cited by 231 · see citing works

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229 · see citing works

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 228 · see citing works

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

Su, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., García-Díaz, Á., Moreno, B. H., Kim, J.-W., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 226 · see citing works

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Sirokay, J. D., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 223 · see citing works

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

O’Connell, M. P., Marchbank, K., Webster, M. R., Valiga, A. A., Kaur, A., Vultur, A., Li, L., Herlyn, M., Villanueva, J., Liu, Q., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0005 · Cited by 223 · see citing works

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα

Smith, M. P., Sánchez‐Laorden, B. L., O’Brien, K., Brunton, H., Ferguson, J., Young, H. L., Dhomen, N. S., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1007 · Cited by 222 · see citing works

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Haq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K. T., PORTER, D. A., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 221 · see citing works

Microphthalmia‐associated transcription factor in melanoma development and MAP ‐kinase pathway targeted therapy

Wellbrock, C., & Arozarena, I. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12370 · Cited by 218 · see citing works

Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities

Rabbie, R., Ferguson, P. M., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2018) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 217 · see citing works

Intravital Imaging Reveals Transient Changes in Pigment Production and Brn2 Expression during Metastatic Melanoma Dissemination

Pinner, S. E., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C. R., & Sahai, E. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0781 · Cited by 202 · see citing works

Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation

Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196 · see citing works

Heterogeneous Tumor Subpopulations Cooperate to Drive Invasion

Chapman, A., del Ama, L. F., Ferguson, J., Kamarashev, J. A., Wellbrock, C., & Hurlstone, A. F. L. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.045 · Cited by 195 · see citing works

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma

O’Connell, M. P., Fiori, J. L., Xu, M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.305 · Cited by 195 · see citing works

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination

Sanborn, Z., Chung, J., Purdom, E. A., Wang, N. J., Kakavand, H., Wilmott, J. S., Butler, T. M., Thompson, J. F., Mann, G. J., Haydu, L. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508074112 · Cited by 186 · see citing works

Systematic classification of melanoma cells by phenotype‐specific gene expression mapping

Widmer, D. S., Cheng, P. F., Eichhoff, O. M., Belloni, B., Zipser, M. C., Schlegel, N. C., Javelaud, D., Mauviel, A., Dummer, R., & Hoek, K. S. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00986.x · Cited by 185 · see citing works

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells

Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V, Hofman, P., Bahadoran, P., Lacour, J.-P., Tartare-Deckert, S., Bertolotto, C., et al. (2012) · Oncogene · doi:10.1038/onc.2011.425 · Cited by 185 · see citing works

c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage

McGill, G. G., Haq, R., Nishimura, E. K., & Fisher, D. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513094200 · Cited by 174 · see citing works

A stress-induced early innate response causes multidrug tolerance in melanoma

Menon, D. R., Das, S. K., Krepler, C., Vultur, A., Rinner, B., Schauer, S., Kashofer, K., Wagner, K., Zhang, G., Rad, E. B., et al. (2014) · Oncogene · doi:10.1038/onc.2014.372 · Cited by 171 · see citing works

GLI2-Mediated Melanoma Invasion and Metastasis

Alexaki, V.-I., Javelaud, D., van Kempen, L. C. L. T., Mohammad, K. S., Dennler, S., Luciani, F., Hoek, K. S., Juárez, P., Goydos, J. S., Fournier, P. G. J., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq257 · Cited by 168 · see citing works

Tumor cell vascular mimicry: Novel targeting opportunity in melanoma

Hendrix, M. J. C., Seftor, E. A., Seftor, R. E. B., Chao, J.-T., Chien, D., & Chu, Y.-W. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.006 · Cited by 162 · see citing works

Whole genome sequencing of matched primary and metastatic acral melanomasPreprint

Turajlic, S., Furney, S. J., Lambros, M. B. K., Mitsopoulos, C., Kozarewa, I., Geyer, F. C., Mackay, A. G., Hakas, J., Zvelebil, M., Lord, C. J., et al. (2011) · Genome Research · doi:10.1101/gr.125591.111 · Cited by 159 · see citing works

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

Kong, X., Kuilman, T., Shahrabi, A., Boshuizen, J., Kemper, K., Song, J., Niessen, H. W. M., Rozeman, E. A., Foppen, M. H. G., Blank, C. U., et al. (2017) · Nature · doi:10.1038/nature24037 · Cited by 152 · see citing works

Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase

Sensi, M., Catani, M., Castellano, G., Nicolini, G., Alciato, F., Tragni, G., Santis, G. D., Bersani, I., Avanzi, G., Tomassetti, A., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.218 · Cited by 148 · see citing works

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

Ahmed, F., & Haass, N. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00173 · Cited by 148 · see citing works

Microenvironment-derived factors driving metastatic plasticity in melanoma

Kim, I. S., Heilmann, S., Kansler, E. R., Zhang, Y., Zimmer, M. A., Ratnakumar, K., Bowman, R. L., Simon-Vermot, T., Fennell, M., Garippa, R. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14343 · Cited by 147 · see citing works

Cancer-associated fibroblasts: how do they contribute to metastasis?

Kwa, M. Q., Herum, K. M., & Brakebusch, C. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09959-0 · Cited by 144 · see citing works

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143 · see citing works

Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1α-Dependent Phenotype Switching

Widmer, D. S., Hoek, K. S., Cheng, P. F., Eichhoff, O. M., Biedermann, T., Raaijmakers, M. I. G., Hemmi, S., Dummer, R., & Levesque, M. P. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.115 · Cited by 139 · see citing works

ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors

Richard, G., Dalle, S., Monet, M., Plaschka, M., Boespflug, A. M., Pommier, R. M., de la Fouchardière, A., Perier‐Muzet, M., Depaepe, L., Barnault, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505971 · Cited by 129 · see citing works

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

Hong, X., Sullivan, R. J., Kalinich, M., Kwan, T. T., Giobbie‐Hurder, A., Pan, S., LiCausi, J. A., Milner, J. D., Nieman, L. T., Wittner, B. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719264115 · Cited by 127 · see citing works

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer

Wellbrock, C., & Arozarena, I. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00033 · Cited by 126 · see citing works

Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing

Miskolczi, Z., Smith, M. P., Rowling, E. J., Ferguson, J., Barriuso, J., & Wellbrock, C. (2018) · Oncogene · doi:10.1038/s41388-018-0209-0 · Cited by 126 · see citing works

Overcoming resistance to BRAF inhibitors

Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 125 · see citing works

Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF

Feige, E., Yokoyama, S., Levy, C., Khaled, M., Igras, V., Lin, R. J., Lee, S., Widlund, H. R., Granter, S. R., Kung, A. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106351108 · Cited by 119 · see citing works

New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis

Rambow, F., Job, B., Petit, V., Gesbert, F., Delmas, V., Seberg, H., Meurice, G., Otterloo, E. V., Dessen, P., Robert, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.037 · Cited by 118 · see citing works

Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation

Dissanayake, S. K., Olkhanud, P. B., O’Connell, M. P., Carter, A., French, A. D., Camilli, T. C., Emeche, C. D., Hewitt, K. J., Rosenthal, D. T., Leotlela, P. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2149 · Cited by 116 · see citing works

Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell

Held, M. A., Curley, D. P., Dankort, D. L., McMahon, M., Muthusamy, V., & Bosenberg, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2153 · Cited by 108 · see citing works

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. F. L., & Wellbrock, C. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 106 · see citing works

Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma

Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0343 · Cited by 105 · see citing works

The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation

Maurus, K., Hufnagel, A., Geiger, F., Graf, S., Berking, C., Heinemann, A., Paschen, A., Kneitz, S., Stigloher, C., Geissinger, E., et al. (2017) · Oncogene · doi:10.1038/onc.2017.135 · Cited by 102 · see citing works

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma

Cheng, P. F., Shakhova, O., Widmer, D. S., Eichhoff, O. M., Zingg, D., Frommel, S. C., Belloni, B., Raaijmakers, M. I., Goldinger, S. M., Santoro, R., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0594-4 · Cited by 100 · see citing works

Benign Melanocytic Nevus Cells in Axillary Lymph Nodes:A Prospective Incidence and Immunohistochemical Study with Literature Review

Bautista, N., Cohen, S., & Anders, K. H. (1994) · American Journal of Clinical Pathology · doi:10.1093/ajcp/102.1.102 · Cited by 95 · see citing works

Recent advances in understanding the complexities of metastasis

Chitty, J. L., Filipe, E. C., Lucas, M. C., Herrmann, D., Cox, T. R., & Timpson, P. (2018) · F1000Research · doi:10.12688/f1000research.15064.2 · Cited by 94 · see citing works

Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1α in Human Melanoma Cells

Spinella, F., Rosanò, L., Castro, V. D., Decandia, S., Nicotra, M. R., Natali, P. G., & Bagnato, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2606 · Cited by 92 · see citing works

Activation of p59Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling

Wellbrock, C., Weisser, C., Geissinger, E., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110684200 · Cited by 92 · see citing works

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Valpione, S., Carlino, M. S., Mangana, J., Mooradian, M. J., McArthur, G. A., Schadendorf, D., Hauschild, A., Menzies, A. M., Arance, A. M., Ascierto, P. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.007 · Cited by 90 · see citing works

W nt5 A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells

Webster, M. R., Xu, M., Kinzler, K. A., Kaur, A., Appleton, J., O’Connell, M. P., Marchbank, K., Valiga, A. A., Dang, V. M., Perego, M., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12330 · Cited by 88 · see citing works

Clonal Architectures and Driver Mutations in Metastatic Melanomas

Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 83 · see citing works

Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells

Perego, M., Tortoreto, M., Tragni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.69 · Cited by 82 · see citing works

The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma

Restivo, G., Diener, J., Cheng, P. F., Kiowski, G., Bonalli, M., Biedermann, T., Reichmann, E., Levesque, M. P., Dummer, R., & Sommer, L. (2017) · Nature Communications · doi:10.1038/s41467-017-01573-6 · Cited by 82 · see citing works

A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells

Jeffs, A. R., Glover, A. C., Slobbe, L. J., Wang, L., He, S., Hazlett, J., Awasthi, A., Woolley, A. G., Marshall, E. S., Joseph, W. R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008461 · Cited by 80 · see citing works

Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth

Ferguson, J., Smith, M. P., Zudaire, I., Wellbrock, C., & Arozarena, I. (2017) · Oncotarget · doi:10.18632/oncotarget.16514 · Cited by 76 · see citing works

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma

Khoja, L., Shenjere, P., Hodgson, C., Hodgetts, J., Clack, G., Hughes, A. M., Lorigan, P. C., & Dive, C. (2013) · Melanoma Research · doi:10.1097/cmr.0000000000000025 · Cited by 75 · see citing works

NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines

Huergo-Zapico, L., Parodi, M., Cantoni, C., Lavarello, C., Fernández‐Martínez, J. L., Petretto, A., deAndrés‐Galiana, E. J., Balsamo, M., López‐Soto, A., Pietra, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1891 · Cited by 75 · see citing works

Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice

da Silva, I. P., & Long, G. V. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000405 · Cited by 74 · see citing works

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607156 · Cited by 74 · see citing works

MITF -High and MITF -Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma

Ennen, M., Keime, C., Gambi, G., Kieny, A., Coassolo, S., Thibault-Carpentier, C., Margerin-Schaller, F., Davidson, G., Vagne, C., Lipsker, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0010 · Cited by 73 · see citing works

Molecular and genetic diversity in the metastatic process of melanoma

Harbst, K., Lauss, M., Cirenajwis, H., Winter, C., Howlin, J., Törngren, T., Kvist, A., Nodin, B., Olsson, E., Häkkinen, J., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4318 · Cited by 71 · see citing works

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 68 · see citing works

HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome

Wardwell‐Ozgo, J., Dogruluk, T., Gifford, A., Zhang, Y., Heffernan, T. P., van Doorn, R., Creighton, C. J., Chin, L., & Scott, K. L. (2013) · Oncogene · doi:10.1038/onc.2013.30 · Cited by 63 · see citing works

CD271 is an imperfect marker for melanoma initiating cells

Chéli, Y., Bonazzi, V., Jacquel, A., Allégra, M., Donatis, G. M. D., Bahadoran, P., Bertolotto, C., & Ballotti, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1967 · Cited by 62 · see citing works

MITF and BRN2 contribute to metastatic growth after dissemination of melanoma

Simmons, J. L., Pierce, C. J., Al‐Ejeh, F., & Boyle, G. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-11366-y · Cited by 61 · see citing works

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Lauss, M., Haq, R., Cirenajwis, H., Phung, B., Harbst, K., Staaf, J., Rosengren, F., Holm, K., Aine, M., Jirström, K., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.61 · Cited by 56 · see citing works

Tumor Cell Plasticity and Angiogenesis in Human Melanomas

Mihic‐Probst, D., Ikenberg, K., Tinguely, M., Schraml, P., Behnke, S., Seifert, B., Civenni, G., Sommer, L., Moch, H., & Dummer, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033571 · Cited by 55 · see citing works

The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report

Eichhoff, O. M., Zipser, M. C., Xu, M., Weeraratna, A. T., Mihic‐Probst, D., Dummer, R., & Hoek, K. S. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32833bd89e · Cited by 54 · see citing works

Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance

Smith, M. P., & Wellbrock, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0954 · Cited by 51 · see citing works

Differentiated melanocyte cell division occurs in vivo and is promoted by mutations in Mitf

Taylor, K. L., Lister, J. A., Zeng, Z., Ishizaki, H., Anderson, C. J., Kelsh, R. N., Jackson, I. J., & Patton, E. E. (2011) · Development · doi:10.1242/dev.064014 · Cited by 50 · see citing works

Erratum: A stress-induced early innate response causes multidrug tolerance in melanoma

Menon, D. R., Das, S. K., Krepler, C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.432 · Cited by 49 · see citing works

Nevus Cell Aggregates in Lymph Nodes

Patterson, J. W. (2004) · American Journal of Clinical Pathology · doi:10.1309/jxe9eyqxd691lv2y · Cited by 47 · see citing works

BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistancePreprint

Ferretti, R., Bhutkar, A. J., McNamara, M. C., & Lees, J. A. (2015) · Genes & Development · doi:10.1101/gad.267757.115 · Cited by 46 · see citing works

Targeting invasive properties of melanoma cells

Arozarena, I., & Wellbrock, C. (2017) · FEBS Journal · doi:10.1111/febs.14040 · Cited by 45 · see citing works

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlow melanoma

Smith, M. P., Rana, S., Ferguson, J., Rowling, E. J., Flaherty, K. T., Wargo, J. A., Marais, R., & Wellbrock, C. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12741 · Cited by 43 · see citing works

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors

Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41 · see citing works

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma

Wiedemann, G. M., Aithal, C., Kraechan, A., Heise, C., Cadilha, B. L., Zhang, J., Duewell, P., Ballotti, R., Endres, S., Bertolotto, C., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.10.014 · Cited by 38 · see citing works

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic Melanoma

Yan, Y., Wongchenko, M. J., Robert, C., Larkin, J., Ascierto, P. A., Dréno, B., Maio, M., Garbe, C., Chapman, P. B., Sosman, J. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0720 · Cited by 38 · see citing works

Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma

Gartner, J. J., Davis, S. R., Wei, X., Lin, J., Trivedi, N. S., Teer, J. K., Program, N. C. S., Meltzer, P. S., Rosenberg, S. A., & Samuels, Y. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-505 · Cited by 37 · see citing works

Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

Brinckerhoff, C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25796 · Cited by 31 · see citing works

[Problems of age-dependent differences in digestion].

Dietze, F., & Brüschke, G. (1970) · PubMed · Cited by 19 · see citing works

Comparison of melanoblast expression patterns identifies distinct classes of genes

Loftus, S. K., Baxter, L. L., Buac, K., et al. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00584.x · Cited by 18 · see citing works

Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma

Viñal, D., Martínez, D., & Espinosa, E. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02028-0 · Cited by 14 · see citing works

Nevus Cell Aggregates in Lymph Nodes

Patterson, J. W. (2004) · American Journal of Clinical Pathology · doi:10.1309/jxe9-eyqx-d691-lv2y · Cited by 14 · see citing works

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138 · see citing works

The great escape: tumour cell plasticity in resistance to targeted therapy

Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 759 · see citing works

From bulk, single-cell to spatial RNA sequencing

Li, X., & Wang, C.-Y. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00146-0 · Cited by 605 · see citing works

Single-cell analysis reveals new evolutionary complexity in uveal melanoma

Durante, M. A., Rodriguez, D. A., Kurtenbach, S., Kuznetsoff, J. N., Sanchez, M. I., Decatur, C. L., Snyder, H., Feun, L. G., Livingstone, A. S., & Harbour, J. W. (2020) · Nature Communications · doi:10.1038/s41467-019-14256-1 · Cited by 456 · see citing works

Emergence of a High-Plasticity Cell State during Lung Cancer Evolution

Marjanovic, N. D., Hofree, M., Chan, J. E., Canner, D. A., Wu, K., Trakala, M., Hartmann, G. G., Smith, O. C. G., Kim, J. Y., Evans, K. V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.012 · Cited by 388 · see citing works

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 403 · see citing works

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 388 · see citing works

The plasticity of mRNA translation during cancer progression and therapy resistance

Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00380-y · Cited by 273 · see citing works

Mechanism of RNA modification N6-methyladenosine in human cancer

Zhou, Z., Lv, J., Yu, H., Han, J., Yang, X. F., Feng, D., Wu, Q., Yuan, B., Lü, Q., & Yang, H. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01216-3 · Cited by 276 · see citing works

Emerging role of tumor cell plasticity in modifying therapeutic response

Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 274 · see citing works

A cellular hierarchy in melanoma uncouples growth and metastasis

Karras, P., Bordeu, I., Poźniak, J., Nowosad, A., Pazzi, C., Raemdonck, N. V., Landeloos, E., Herck, Y. V., Pedri, D., Bervoets, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05242-7 · Cited by 251 · see citing works

Melanoma models for the next generation of therapies

Patton, E. E., Mueller, K. L., Adams, D. J., Anandasabapathy, N., Aplin, A. E., Bertolotto, C., Bosenberg, M., Ceol, C. J., Burd, C. E., Chi, P., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.011 · Cited by 204 · see citing works

Tumor Functional Heterogeneity Unraveled by scRNA-seq Technologies

González-Silva, L., Quevedo, L., & Varela, I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.11.010 · Cited by 200 · see citing works

The journey from melanocytes to melanoma

Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 202 · see citing works

Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma

Marín-Béjar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Poźniak, J., Bervoets, G., Raemdonck, N. V., Pedri, D., Swings, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.015 · Cited by 143 · see citing works

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136 · see citing works

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Pérez‐Guijarro, E., Yang, H. H., Araya, R. E., Meskini, R. E., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 115 · see citing works

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 119 · see citing works

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity

Wright, S. C. E., Vasilevski, N., Serra, V., Rodon, J. A., & Eichhorn, P. J. A. (2021) · Cancers · doi:10.3390/cancers13071538 · Cited by 110 · see citing works

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance

Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 108 · see citing works

Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis

Huang, X., Pang, M.-J., Li, J.-Y., Chen, H., Sun, J., Song, Y., Ni, H.-J., Ye, S.-Y., Bai, S., Li, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36310-9 · Cited by 106 · see citing works

ZEB1 transcription factor promotes immune escape in melanoma

Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Bouar, M. L., Balme, B., Tondeur, G., de la Fouchardière, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003484 · Cited by 96 · see citing works

The role of gut microbiota and metabolites in cancer chemotherapy

Li, S., Zhu, S., & Yu, J. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.027 · Cited by 106 · see citing works

EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment

Tang, Y., Durand, S., Dalle, S., & Caramel, J. (2020) · Cancers · doi:10.3390/cancers12082154 · Cited by 96 · see citing works

Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling

Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K., & Spencer, S. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21549-x · Cited by 94 · see citing works

ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL

Pietrobono, S., Anichini, G., Sala, C., Manetti, F., Almada, L. L., Pepe, S., Carr, R. M., Paradise, B. D., Sarkaria, J. N., Davila, J. I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19575-2 · Cited by 90 · see citing works

Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance

Hossain, S. M., & Eccles, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021601 · Cited by 89 · see citing works

MITF reprograms the extracellular matrix and focal adhesion in melanoma

Dilshat, R., Fock, V., Kenny, C., Gerritsen, I., Lasseur, R. M. J., Trávníčková, J., Eichhoff, O. M., Cerny, P., Möller, K., Sigurbjörnsdóttir, S., et al. (2021) · eLife · doi:10.7554/elife.63093 · Cited by 82 · see citing works

Cellular and molecular mechanisms of plasticity in cancer

Torborg, S. R., Li, Z., Chan, J. E., & Tammela, T. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.007 · Cited by 83 · see citing works

Exosome camouflaged coordination-assembled Iridium(III) photosensitizers for apoptosis-autophagy-ferroptosis induced combination therapy against melanoma

Feng, T., Tang, Z., Karges, J., Shen, J., Jin, C., Chen, Y., Pan, Y., He, Y., Ji, L., & Chao, H. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122212 · Cited by 84 · see citing works

A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer

Liu, L., Yan, L., Liao, N., Wu, W.-Q., & Shi, J. (2020) · Cancers · doi:10.3390/cancers12020352 · Cited by 84 · see citing works

Melanoma Cell Membrane Biomimetic Versatile CuS Nanoprobes for Homologous Targeting Photoacoustic Imaging and Photothermal Chemotherapy

Wu, M., Mei, T., Lin, C., Wang, Y., Chen, J., Le, W., Sun, M., Xu, J., Dai, H., Zhang, Y., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b23177 · Cited by 81 · see citing works

Chlorin e6 and CRISPR-Cas9 dual-loading system with deep penetration for a synergistic tumoral photodynamic-immunotherapy

Yang, C., Fu, Y., Huang, C. Z., Hu, D., Zhou, K., Hao, Y., Chu, B., Yang, Y., & Qian, Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120194 · Cited by 79 · see citing works

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

Gibson, F. T., Hanly, A. M., Grbic, N., Grunberg, N., Wu, M., Collard, M., & Alani, R. M. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08956-8 · Cited by 79 · see citing works

Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis

Han, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 72 · see citing works

Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape

Romano, V., Belviso, I., Venuta, A., Ruocco, M. R., Masone, S., Aliotta, F., Fiume, G., Montagnani, S., Avagliano, A., & Arcucci, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105283 · Cited by 73 · see citing works

Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer

Groves, S. M., Ildefonso, G. V., McAtee, C. O., Ozawa, P. M. M., Ireland, A. S., Stauffer, P. E., Wasdin, P. T., Huang, X., Qiao, Y., Lim, J. S., et al. (2022) · Cell Systems · doi:10.1016/j.cels.2022.07.006 · Cited by 64 · see citing works

Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation

Bala, P., Rennhack, J. P., Aitymbayev, D., Morris, C. X., Moyer, S. M., Duronio, G. N., Doan, K. T., Li, Z., Liang, X., Hornick, J. L., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf0927 · Cited by 67 · see citing works

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response

Cabrita, R., Mitra, S., Sanna, A., Ekedahl, H., Lövgren, K., Olsson, H. L., Ingvar, C., Isaksson, K., Lauss, M., Carneiro, A., et al. (2020) · Cancers · doi:10.3390/cancers12030742 · Cited by 66 · see citing works

Loss of Ambra1 promotes melanoma growth and invasion

Leo, L. D., Bodemeyer, V., Bosisio, F. M., Claps, G., Carretta, M., Rizza, S., Faienza, F., Frías, A., Khan, S., Bordi, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22772-2 · Cited by 62 · see citing works

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses

Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 63 · see citing works

Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy

Huang, F., Santinon, F., González, R. E. F., & Rincon, S. V. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756001 · Cited by 61 · see citing works

Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment

Hodis, E., Triglia, E. T., Kwon, J., Biancalani, T., Zakka, L. R., Parkar, S., Hütter, J.-C., Buffoni, L., Delorey, T. M., Phillips, D., et al. (2022) · Science · doi:10.1126/science.abi8175 · Cited by 59 · see citing works

Bioengineered Platelets Combining Chemotherapy and Immunotherapy for Postsurgical Melanoma Treatment: Internal Core-Loaded Doxorubicin and External Surface-Anchored Anti-PD-L1 Antibody Backpacks

Qi, L., Ye, H., Wang, K., Zhao, J., Wang, H., Song, J., Fan, X., Lu, Y., Cao, L., Wan, B., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00907 · Cited by 61 · see citing works

Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

Redondo-Muñoz, M., Rodríguez‐Baena, F. J., Aldaz, P., Caballé, A., Moncho-Amor, V., Otaegi-Ugartemendia, M., Carrasco‐García, E., Olías-Arjona, A., Lasheras-Otero, I., Santamaría, E., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00861-4 · Cited by 61 · see citing works

A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options

Sun, L., Kang, X., Ju, H., Wang, C., Yang, G., Wang, R., & Sun, S. (2023) · Science Advances · doi:10.1126/sciadv.adg6686 · Cited by 58 · see citing works

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

Hartman, M. L., Sztiller-Sikorska, M., Gajos-Michniewicz, A., & Czyż, M. (2020) · Cells · doi:10.3390/cells9010142 · Cited by 56 · see citing works

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Massi, D., Mihic‐Probst, D., Schadendorf, D., Dummer, R., & Mandalà, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102060 · Cited by 56 · see citing works

Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance

Dratkiewicz, E., Simiczyjew, A., Mazurkiewicz, J., Ziętek, M., Matkowski, R., & Nowak, D. (2021) · Cells · doi:10.3390/cells10040862 · Cited by 59 · see citing works

Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles

Li, S., Bennett, Z. T., Sumer, B. D., & Gao, J. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00475 · Cited by 56 · see citing works

Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors

Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 59 · see citing works

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Farshidfar, F., Rhrissorrakrai, K., Levovitz, C., Peng, C., Knight, J., Bacchiocchi, A., Su, J., Yin, M., Sznol, M., Ariyan, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28566-4 · Cited by 58 · see citing works

Cell Adhesion Molecules in Plasticity and Metastasis

Smart, J. A., Oleksak, J. E., & Hartsough, E. J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0595 · Cited by 54 · see citing works

Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2

Xu, Y., Wang, H., Li, F., Heindl, L. M., He, X., Yu, J., Yang, J., Ge, S., Ruan, J., Jia, R., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00350 · Cited by 53 · see citing works

The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance

Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 54 · see citing works

The Intimate Relationship among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes

Hass, R., von der Ohe, J., & Ungefroren, H. (2020) · Cancers · doi:10.3390/cancers12123674 · Cited by 53 · see citing works

Living Bacteria‐Based Immuno‐Photodynamic Therapy: Metabolic Labeling of Clostridium butyricum for Eradicating Malignant Melanoma

Shi, L., Liu, X., Li, Y., Li, S., Wu, W., Gao, X., & Liu, B. (2022) · Advanced Science · doi:10.1002/advs.202105807 · Cited by 48 · see citing works

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma

Fattore, L., Ruggiero, C. F., Liguoro, D., Mancini, R., & Ciliberto, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2048-5 · Cited by 48 · see citing works

Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 47 · see citing works

Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanoma

Huang, F., Cai, F., Dahabieh, M. S., Gunawardena, K., Talebi, A., Dehairs, J., El-Turk, F., Park, J. Y., Li, M., Gonçalves, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166644 · Cited by 46 · see citing works

ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming

Li, F., Yuan, Q., Di, W., Xia, X., Liu, Z., Mao, N., Li, L., Li, C., He, J., Li, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137967 · Cited by 46 · see citing works

RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy

Radaszkiewicz, T. W., Nosková, M., Gömöryová, K., Blanářová, O. V., Radaszkiewicz, K. A., Pícková, M., Víchová, R., Gybeľ, T., Kaiser, K., Demková, L., et al. (2021) · eLife · doi:10.7554/elife.65759 · Cited by 46 · see citing works

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge

Florent, L., Saby, C., Slimano, F., & Morjani, H. (2023) · Cancers · doi:10.3390/cancers15092607 · Cited by 46 · see citing works

How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance

Wessely, A., Steeb, T., Berking, C., & Heppt, M. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115761 · Cited by 45 · see citing works

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors

Motti, M. L., Minopoli, M., Carluccio, G. D., Ascierto, P. A., & Carriero, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124544 · Cited by 45 · see citing works

Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance

Popovic, A., & Tartare-Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 42 · see citing works

Application of single-cell sequencing to the research of tumor microenvironment

Chen, S., Zhou, Z., Li, Y., Du, Y., & Chen, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285540 · Cited by 43 · see citing works

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy

Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 40 · see citing works

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma

Palamaris, K., Moutafi, M. K., Gakiopoulou, H., & Theocharis, S. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073660 · Cited by 42 · see citing works

Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process

Melixetian, M. B., Pelicci, P. G., & Lanfrancone, L. (2022) · Cells · doi:10.3390/cells11030577 · Cited by 40 · see citing works

Unveiling functional heterogeneity in breast cancer multicellular tumor spheroids through single-cell RNA-seq

Muciño-Olmos, E. A., Vázquez-Jiménez, A., de León, U. A.-P., Matadamas-Guzman, M. L., Maldonado, V., López-Santaella, T., Hernández‐Hernández, A., & Reséndis-Antonio, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-69026-7 · Cited by 39 · see citing works

Actin dynamics during tumor cell dissemination

(2021) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2020.09.004 · Cited by 39 · see citing works

Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment

Kharouf, N., Flanagan, T. W., Hassan, S.-Y., Shalaby, H., Khabaz, M., Hassan, S.-L., Megahed, M., Haïkel, Y., Santourlidis, S., & Hassan, M. (2023) · Cancers · doi:10.3390/cancers15123147 · Cited by 40 · see citing works

Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapy

Silvestrini, A. V. P., Morais, M. F., Debiasi, B. W., Praça, F. S. G., & Bentley, M. V. L. B. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115198 · Cited by 40 · see citing works

Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency

Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 37 · see citing works

mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer

Lv, G., Wang, Q., Lin, L., Ye, Q., Li, X., Zhou, Q., Kong, X., Deng, H., You, F., Chen, H., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01473-0 · Cited by 38 · see citing works

Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies

Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2020) · Cancers · doi:10.3390/cancers12061364 · Cited by 36 · see citing works

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs

Sharko, A. C., Lim, C., McDermott, M. S. J., Hennes, C., Philavong, K. P., Aiken, T., Tatarskiy, V. V., Roninson, I. B., & Broude, E. V. (2021) · Cells · doi:10.3390/cells10010144 · Cited by 37 · see citing works

Combined heterogeneity in cell size and deformability promotes cancer invasiveness

Asadullah, Kumar, S., Saxena, N., Sarkar, M., Barai, A., & Sen, S. (2021) · Journal of Cell Science · doi:10.1242/jcs.250225 · Cited by 35 · see citing works

Blockade of the pro‐fibrotic reaction mediated by the miR‐143/‐145 cluster enhances the responses to targeted therapy in melanoma

Diazzi, S., Baeri, A., Fassy, J., Lecacheur, M., Marín-Béjar, O., Girard, C. A. J., Lefevre, L., Lacoux, C., Irondelle, M., Mounier, C. M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115295 · Cited by 33 · see citing works

Advances in targeted therapy and immunotherapy for melanoma (Review)

Qin, Z., & Zheng, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12115 · Cited by 35 · see citing works

Peptide-Based Double-Network Hydrogels for Melanoma Treatment and Wound Healing Promotion

Hou, Y., Tian, Y., Tian, J., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c03854 · Cited by 33 · see citing works

Revolutionizing cancer treatment: The power of cell-based drug delivery systems

Qi, L., Liu, T., Han, Z., Zhao, J., Fan, X., Wang, H., Song, J., Ye, H., & Sun, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.023 · Cited by 33 · see citing works

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy

Beigi, Y. Z., Lanjanian, H., Fayazi, R., Salimi, M., Hoseyni, B. H. M., Noroozizadeh, M. H., & Masoudi‐Nejad, A. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00182-2 · Cited by 33 · see citing works

RAS pathway regulation in melanoma

Mahi, A. A., & Ablain, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049229 · Cited by 32 · see citing works

The future of targeted kinase inhibitors in melanoma

Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 33 · see citing works

Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest

Tang, J., Li, G., Zhang, T., Du, Y.-M., Huang, S., Ran, J., Li, J., & Chen, D. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108774 · Cited by 32 · see citing works

Human Endogenous Retrovirus K Rec Forms a Regulatory Loop with MITF that Opposes the Progression of Melanoma to an Invasive Stage

Singh, M., Cai, H., Bunse, M., Feschotte, C., & Izsvák, Z. (2020) · Viruses · doi:10.3390/v12111303 · Cited by 31 · see citing works

Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation

Melixetian, M. B., Bossi, D., Mihailovich, M., Punzi, S., Barozzi, I., Marocchi, F., Cuomo, A., Bonaldi, T., Testa, G., Marine, J., et al. (2021) · EMBO Reports · doi:10.15252/embr.202050852 · Cited by 31 · see citing works

Intermittent treatment of BRAF V600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge

Kavran, A. J., Stuart, S. A., Hayashi, K. R., Basken, J., Brandhuber, B. J., & Ahn, N. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113535119 · Cited by 31 · see citing works

Mesenchymal Stem Cell-Derived Extracellular Vesicles in Cancer Therapy Resistance: from Biology to Clinical Opportunity

Shan, C., Yan, L., Wang, K., & Li, P. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.88500 · Cited by 32 · see citing works

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma

Audrito, V., Messana, V. G., Moiso, E., Vitale, N., Arruga, F., Brandimarte, L., Gaudino, F., Pellegrino, E., Vaisitti, T., Riganti, C., et al. (2020) · Cancers · doi:10.3390/cancers12123855 · Cited by 30 · see citing works

The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma

Lasheras-Otero, I., Feliu, I., Maillo, A., Moreno, H., Redondo-Muñoz, M., Aldaz, P., Bocanegra, A., Olías-Arjona, A., Lecanda, F., Fernández‐Irigoyen, J., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.08.038 · Cited by 30 · see citing works

Emerging roles of endoplasmic reticulum stress in the cellular plasticity of cancer cells

Wang, H., & Mi, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1110881 · Cited by 30 · see citing works

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma

Guida, M., Bartolomeo, N., Risi, I. D., Fucci, L., Armenio, A., Filannino, R., Ruggieri, E., Macina, F., Traversa, M., Nardone, A., et al. (2019) · Cancers · doi:10.3390/cancers11101559 · Cited by 28 · see citing works

CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1

Luo, H., Zhou, Z., Huang, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04114-8 · Cited by 28 · see citing works

Multi-modal molecular programs regulate melanoma cell state

Andrews, M. C., Oba, J., Wu, C., Zhu, H., Karpinets, T. V., Creasy, C. A., Forget, M., Yu, X., Song, X., Mao, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31510-1 · Cited by 32 · see citing works

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 30 · see citing works

New Insights into the Phenotype Switching of Melanoma

Pagliuca, C., Leo, L. D., & Zio, D. D. (2022) · Cancers · doi:10.3390/cancers14246118 · Cited by 28 · see citing works

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma

Grzywa, T. M., Klicka, K., Paskal, W., Dudkiewicz-Garbicz, J., Wejman, J., Pyźlak, M., & Wlodarski, P. K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234707 · Cited by 26 · see citing works

Associated costs and benefits of a defended phenotype across multiple environments

Moran, D. T., Dias, G. M., & Marshall, D. J. (2010) · Functional Ecology · doi:10.1111/j.1365-2435.2010.01741.x · Cited by 15 · see citing works

Comparison of morphological and physiological characteristics in two phenotypes of a rare and endangered plant, Begonia fimbristipula Hance

Wang, Y., Shao, L., Wang, J., et al. (2016) · Photosynthetica · doi:10.1007/s11099-016-0199-5 · Cited by 12 · see citing works

Direct and Indirect Induction of a Compensatory Phenotype that Alleviates the Costs of an Inducible Defense

Iwami, T., Kishida, O., & Nishimura, K. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001084 · Cited by 24 · see citing works

The molecular basis of socially mediated phenotypic plasticity in a eusocial paper wasp

Taylor, B. A., Cini, A., Wyatt, C. D. R., Reuter, M., & Sumner, S. (2021) · Nature Communications · doi:10.1038/s41467-021-21095-6 · Cited by 46 · see citing works

The molecular basis of socially-mediated phenotypic plasticity in a eusocial paper waspPreprint

Taylor, B., Cini, A., Wyatt, C. D. R., Reuter, M., & Sumner, S. (2020) · Research Square · doi:10.21203/rs.3.rs-43815/v1 · Cited by 1 · see citing works